Is the 13‑valent pneumococcal conjugate vaccine (PCV13) administered as a single dose and does it provide lifelong immunity?

PCV13 Dosing: Single Dose, Not Lifetime Protection

PCV13 (Prevnar 13) is administered as a single dose in adults, but it does NOT provide lifelong immunity—current guidelines now recommend transitioning to higher-valent vaccines (PCV20 or PCV21) to complete the pneumococcal vaccination series. 1

Current Vaccination Strategy

PCV13 Is No Longer the Endpoint

• The CDC now recommends that adults who previously received only PCV13 should receive a single dose of PCV20 at least 1 year after the PCV13 dose to complete their pneumococcal vaccination series. 1
• Once PCV20 is administered, the pneumococcal vaccination series is complete and no additional pneumococcal vaccines are needed. 1
• PCV13 alone is no longer considered adequate protection—it has been superseded by broader-coverage conjugate vaccines. 1

Why PCV13 Alone Is Insufficient

• PCV13 covers only 13 pneumococcal serotypes, whereas PCV20 provides protection against 20 serotypes, including the 7 additional serotypes that cause significant disease in adults. 1
• Conjugate vaccines like PCV20 have immunologic advantages including T-cell dependent responses and immunologic memory that make them superior to polysaccharide vaccines. 1
• Phase III trials demonstrated that PCV20 is safe and immunogenic in adults previously vaccinated with PCV13, regardless of the interval between doses (6 months to 5 years). 1

Immunologic Duration of PCV13

Antibody Persistence

• While PCV13 elicits robust immune responses initially (geometric mean fold rises ranging from 6.6 to 102.7 across all 13 serotypes), antibody titers decline after one year but remain above baseline. 2
• The vaccine does NOT provide permanent, lifelong immunity—antibody levels wane over time, which is why completion with PCV20 is now recommended. 2

Real-World Effectiveness Data

• In a large observational study of adults ≥65 years, PCV13 demonstrated 61.5% vaccine effectiveness (95% CI: 36.2–76.7) against PCV13-serotype invasive pneumococcal disease. 3
• Notably, serotype 3 cases have persisted despite PCV13 use, with effectiveness against serotype 3 IPD only 46.3% (95% CI: -2.4–77.9), highlighting the limitations of PCV13 coverage. 3

Practical Clinical Algorithm

For Adults Who Received PCV13 Only

1. Verify that at least 1 year has elapsed since the PCV13 dose. 1
2. Administer a single dose of PCV20 (or PCV21) to complete the series. 1
3. Document that the pneumococcal vaccination series is now complete—no further doses are needed. 1

For Adults Who Received Both PCV13 and PPSV23

• If PPSV23 was given before age 65, administer PCV20 ≥5 years after the last pneumococcal vaccine dose through shared clinical decision-making. 1
• If PPSV23 was given at age ≥65, shared clinical decision-making is recommended regarding PCV20 administration ≥5 years after the last dose, though this is optional. 1

For Immunocompromised Adults

• The same ≥1 year interval after PCV13 applies before giving PCV20. 1
• Immunocompromised patients do not require shorter intervals between PCV20 doses, eliminating the complexity of sequential regimens. 1

Common Pitfalls to Avoid

• Do not assume PCV13 provides lifelong protection—it requires completion with PCV20 for optimal coverage. 1
• Do not give PCV20 too soon—the 1-year minimum interval after PCV13 must be observed for optimal immune response. 1
• Do not add PPSV23 after PCV20—once PCV20 is administered, the series is complete and adding PPSV23 is unnecessary and not recommended. 1
• Do not confuse the 1-year interval (for PCV13 alone) with the 5-year interval (for both PCV13 and PPSV23 previously given)—these are distinct clinical scenarios. 1

Special Consideration: Hematopoietic Stem Cell Transplant Recipients

• Adults who received HSCT require a unique 4-dose series of PCV20 starting 3–6 months after HSCT, with the first 3 doses given 4 weeks apart and the fourth dose at least 6 months after the third dose or at least 12 months after HSCT, whichever is later. 1